Molecular Formula | C21H26O6 |
Molar Mass | 374.43 |
Density | 1.226 |
Melting Point | 80-82℃ |
Boling Point | 622.6±55.0 °C(Predicted) |
Specific Rotation(α) | -10 (c, 0.28 in CHCl3) |
Flash Point | 218℃ |
Solubility | Chloroform (Sparingly), Ethyl Acetate (Slightly), DCM, DMSO |
Appearance | neat |
Color | Pale Yellow |
BRN | 2486876 |
pKa | 10.02±0.20(Predicted) |
Storage Condition | 2-8°C |
WGK Germany | 3 |
Reference Show more | 1. [IF=4.946] Lai Yanni et al."3D-quantitative structure–activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase."Arch Pharm Res. 2020 May;43(5):489-502 |
biological activity | hexahydrocurrumin is one of the main metabolites of curcumin, which is a selective orally active COX-2 inhibitor, no activity on COX-1. Hexahydrocurrumin has antioxidant, anticancer and anti-inflammatory effects. |
Cell Line: | HT-29 cells HT-29 cells HT-29 cells |
Concentration: | 0 µM, 5 µM, 10 µM, 25 µM 25 µM 25 µM |
Incubation Time: | 24 hours or 48 hours 24 hours 24 hours |
Result: | Significantly decreased the viability of HT-29 colon cancer cells. Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 expression. Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 protein. Significantly reduced the numbers of ACF in colon cancer rats. Also markedly decreased COX-2 protein expression. |
Animal Model: | Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH) |
Dosage: | 50 mg/kg |
Administration: | Oral administration; daily; for 16 weeks |